Autoantibodies Predict Severity of IgA NephropathyLast Updated: August 17, 2012. Serum levels of autoantibodies to immunoglobulin G and A and the modified galactose-deficient IgA1, seen in IgA nephropathy, are strongly associated with disease progression, according to a study published online Aug. 16 in the Journal of the American Society of Nephrology.
FRIDAY, Aug. 17 (HealthDay News) -- Serum levels of autoantibodies to immunoglobulin G (IgG) and A (IgA) and the modified galactose-deficient IgA1 (Gd-IgA1), seen in IgA nephropathy (IgAN), are strongly associated with disease progression, according to a study published online Aug. 16 in the Journal of the American Society of Nephrology.
Francois Berthoux, M.D., of University North Hospital in Saint-Etienne, France, and colleagues conducted a study using serum samples from 97 patients newly diagnosed with IgAN who were part of a prospective cohort study to assess absolute renal risk for progression to dialysis/death. Serum levels of modified Gd-IgA1 and IgG and IgA autoantibodies were measured and compared with 30 healthy controls and 30 patients with non-IgAN disease. The levels were correlated with outcome findings after a mean of 13.8 years.
The researchers found that, in patients with IgAN, mean serum levels of total autoantigen, normalized IgG autoantibody, and total IgA autoantibody were significantly higher than in the combined controls. In patients with worse clinical outcomes, the levels were higher in a stepwise pattern. Serum IgG autoantibody levels were predictive of dialysis/death.
"This paper is a first step, and in the future we have to refine these tests to check the impact of different treatments on these serum biomarkers, and to imagine new therapies with direct impacts on modified IgA1 or on the specific antibody responses against it," Berthoux said in a statement.
|Previous: Vancomycin Overprescribed in Bloodstream MSSA Infections||Next: Even Minor Changes in Physical Activity Improve Bone Health|
Reader comments on this article are listed below. Review our comments policy.